I Khromova
Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe
Santos J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren J, Bogner J, Duvivier C, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, EuroSIDA Study Group. Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. HIV Med 2018; 19:324-338.
01.02.2018Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe
01.02.2018HIV Med 2018; 19:324-338
Santos J R, Gargalianos-Kakolyris P, Schmid Patrick, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren J D, Bogner J, Duvivier C, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, EuroSIDA Study Group
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens
Cozzi-Lepri A, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso M, Lundgren J, Mocroft A, Gottfredsson M, Schmid P, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, EuroSIDA Study Group. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Med 2017
06.10.2017Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens
06.10.2017HIV Med 2017
Cozzi-Lepri A, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso M H, Lundgren J D, Mocroft A, Gottfredsson M, Schmid Patrick, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, EuroSIDA Study Group